Tags

Type your tag names separated by a space and hit enter

Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome.
Aliment Pharmacol Ther 2007; 26(3):463-73AP

Abstract

BACKGROUND

A multispecies probiotic has shown beneficial effects in irritable bowel syndrome. In addition, certain other probiotics have demonstrated advantageous effects, but the mechanisms behind this are poorly understood.

AIM

To investigate the mode of action of a multispecies probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99 by monitoring its effects on intestinal microbiota and markers of microbial activity.

METHODS

A total of 55 irritable bowel syndrome patients participated in this placebo-controlled double-blind trial. Subjects received either multispecies probiotic or placebo supplementation daily during a 6-month period. The composition of intestinal microbiota was analysed with real-time polymerase chain reaction, short-chain fatty acids with gas chromatography and enzymes with spectrophotometer.

RESULTS

Each supplemented probiotic strain was detected in faecal samples. Intestinal microbiota remained stable during the trial, except for Bifidobacterium spp., which increased in the placebo group and decreased in the probiotic group (P = 0.028). No changes in short-chain fatty acids occurred. A decrease in ss-glucuronidase activity was detected in 67% of the subjects in the probiotic group vs. 38% in the placebo group (P = 0.06).

CONCLUSIONS

Factors other than the microbial groups and metabolites studied herein seem responsible for the alleviation of irritable bowel syndrome symptoms by the multispecies probiotic.

Authors+Show Affiliations

Institute of Biomedicine, Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17635381

Citation

Kajander, K, et al. "Effects of Multispecies Probiotic Supplementation On Intestinal Microbiota in Irritable Bowel Syndrome." Alimentary Pharmacology & Therapeutics, vol. 26, no. 3, 2007, pp. 463-73.
Kajander K, Krogius-Kurikka L, Rinttilä T, et al. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(3):463-73.
Kajander, K., Krogius-Kurikka, L., Rinttilä, T., Karjalainen, H., Palva, A., & Korpela, R. (2007). Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 26(3), pp. 463-73.
Kajander K, et al. Effects of Multispecies Probiotic Supplementation On Intestinal Microbiota in Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2007 Aug 1;26(3):463-73. PubMed PMID: 17635381.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. AU - Kajander,K, AU - Krogius-Kurikka,L, AU - Rinttilä,T, AU - Karjalainen,H, AU - Palva,A, AU - Korpela,R, PY - 2007/7/20/pubmed PY - 2007/12/15/medline PY - 2007/7/20/entrez SP - 463 EP - 73 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 26 IS - 3 N2 - BACKGROUND: A multispecies probiotic has shown beneficial effects in irritable bowel syndrome. In addition, certain other probiotics have demonstrated advantageous effects, but the mechanisms behind this are poorly understood. AIM: To investigate the mode of action of a multispecies probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99 by monitoring its effects on intestinal microbiota and markers of microbial activity. METHODS: A total of 55 irritable bowel syndrome patients participated in this placebo-controlled double-blind trial. Subjects received either multispecies probiotic or placebo supplementation daily during a 6-month period. The composition of intestinal microbiota was analysed with real-time polymerase chain reaction, short-chain fatty acids with gas chromatography and enzymes with spectrophotometer. RESULTS: Each supplemented probiotic strain was detected in faecal samples. Intestinal microbiota remained stable during the trial, except for Bifidobacterium spp., which increased in the placebo group and decreased in the probiotic group (P = 0.028). No changes in short-chain fatty acids occurred. A decrease in ss-glucuronidase activity was detected in 67% of the subjects in the probiotic group vs. 38% in the placebo group (P = 0.06). CONCLUSIONS: Factors other than the microbial groups and metabolites studied herein seem responsible for the alleviation of irritable bowel syndrome symptoms by the multispecies probiotic. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/17635381/Effects_of_multispecies_probiotic_supplementation_on_intestinal_microbiota_in_irritable_bowel_syndrome_ L2 - https://doi.org/10.1111/j.1365-2036.2007.03391.x DB - PRIME DP - Unbound Medicine ER -